-
Sarepta’s Gene Therapy for DMD Showing to Safety, Efficacy at One Year
Four Duchenne boys given SRP-9001, a micro-dystrophin gene therapy, continue to show better muscle strength and safety at one year in a Phase 1/2 trial. Read more about their results here.
What do you think of this news?
Sorry, there were no replies found.
Log in to reply.